N7. I had looked at EYPT but went with OCUL instead because of the team they had assembled , how fast the trials were enrolling , safety data etc . OCUL will have the first pivotal P 3 trial data .....SOL-1 in Q4 2025 . Their SOL-R trial now has 311 randomized ( I need to chk the total number they were aiming for ) . If both trials are successful they will file for approval to treat wet AMD . Bottom line ....if all goes well they will have an approved drug well before EYPT.
Meanwhile this field is not standing still VABYSMO seems to be the new eye drug of choice ...lasting 3-4 mths for 78 % of those getting this eye injection . OCUL's AXPAXLI is expected to last up to 10 mths . My Kaiser eye doc tells me the biggest problem with Eyelea ( Afliberecept ) is most patients won't stick to the repeat dosing if they need an eye injection every 2-3 mths.. I think AXPAXL ( OCUL ) and Eyelea have similar safety profiles . Its a long term hold for me . Been distracted with other things recently ( clearing shrubs , brush from around my house , setting up fire suppression sprinklers etc ) I'm in Nth Ca and surround by trees . Area has a history of bad fires ...so everyone here is a little on edge after what happened in LA
Market Data 
Markets 
AI
